"The implementation of PRDT's prion removal resin into the manufacturing process of Octaplas(R) to further improve the prion safety margin documented for this biopharmaceutical is regarded as a natural product lifecycle evolution, according to both our Company's pathogen safeguarding policy and regulatory guidelines in force," underlined Kim Bjornstrup, Deputy Chairman of the Octapharma Group.
"Publication of data on the utility of the prion removal resin by Octapharma is testimony to the efficacy of the product manufactured by ProMetic," commented Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer. "We commend Octapharma for taking a proactive stance against vCJD by investigation of a further safety feature to their process".
The PRDT prion removal technology is presently being used in the P-Capt(R) prion filter, CE marked in September 2006, and marketed by MacoPharma for the elimination of TSEs such as vCJD in red blood cell concentrates.
About Variant Creutzfeldt-Jakob Disease
Variant Creutzfeldt-Jakob disease ("vCJD") is a fatal central nervous
system disorder which incubates without symptoms for ten years or more
before beginning an inexorable clinical progression to death over a 6 to 24
months period. vCJD first appeared in 1996 following a massive exposure of
the UK population to Bovine Spongiform Encephalopathy ("BSE"; 'Mad Cow
Disease') contaminated meat and other bovine products during the previous
decade. So far, most of the infections have occurred in children and young
adults who accumulate characteristic depositions of misfolded prion
proteins in their brains and other nervous tissues. The death of neurons
gives a sponge-like appearance to the brain. Even though the fir
|SOURCE PROMETIC LIFE SCIENCES INC.|
Copyright©2008 PR Newswire.
All rights reserved